Moore Kuehn Encourages SOVO, DBTX, DM and ZYNE Investors to Contact Law Firm
September 07, 2023 10:15 ET
|
Moore Kuehn
NEW YORK, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims...
Moore Kuehn Encourages CTG, KLR, ZYNE, and DBTX Investors to Contact Law Firm
August 31, 2023 10:32 ET
|
Moore Kuehn
NEW YORK, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims...
Moore Kuehn Encourages AMED, DBTX, RETA, and SURF Investors to Contact Law Firm
August 29, 2023 11:47 ET
|
Moore Kuehn
NEW YORK, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims...
Moore Kuehn Encourages DBTX, AVID, CPRI, and ARCE Investors to Contact Law Firm
August 22, 2023 13:30 ET
|
Moore Kuehn
NEW YORK, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims...
DBTX Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Decibel Therapeutics to Regeneron Pharmaceuticals
August 09, 2023 09:31 ET
|
Wohl & Fruchter LLP
MONSEY, N.Y., Aug. 09, 2023 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the $4.00 per share in cash, plus a contingent value right (“CVR”) for up to...
Decibel Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Update
August 10, 2022 16:30 ET
|
Decibel Therapeutics, Inc.
- Announced positive data from interim analysis of Phase 1b clinical trial of DB-020 in patients receiving cisplatin chemotherapy; data support continued development of DB-020 as a potential therapy...
Decibel Therapeutics Reports Positive Data from Interim Analysis of Ongoing Phase 1b Clinical Trial of DB-020 in Patients Receiving Cisplatin Chemotherapy
June 28, 2022 07:00 ET
|
Decibel Therapeutics, Inc.
- 87% of patients who experienced ototoxicity in their placebo-treated ear were protected from ototoxicity in their DB-020-treated ear – - Data support continued development of DB-020 as a potential...
Decibel Therapeutics to Present at the H.C. Wainwright Global Investment Conference
May 17, 2022 07:30 ET
|
Decibel Therapeutics, Inc.
BOSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel Therapeutics Reports First Quarter 2022 Financial Results and Corporate Update
May 12, 2022 07:30 ET
|
Decibel Therapeutics, Inc.
- Multiple milestones anticipated for 2022 including submission of IND and/or CTA for DB-OTO, top-line results from interim analysis of Phase 1b trial of DB-020 for cisplatin-induced hearing loss and...
Decibel Therapeutics to Present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting
May 02, 2022 07:30 ET
|
Decibel Therapeutics, Inc.
BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...